Evolving Role of Mass Spectrometry in Drug Discovery and Development

Mass Spectrometry in Drug Metabolism and Pharmacokinetics

Volumn , Issue , 2008, Pages 1-85

  Ramanathan, Dil M ^a   Lelacheur, Richard M ^b  

^a KEAN UNIVERSITY   (United States)

^b Taylor Technology Inc   (United States)

Author keywords

Drug discovery and development mass spectrometry; Quantitative analysis mass spectrometry; Sample preparation cleanup and column technology

Indexed keywords

EID: 79953668060     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470409817.ch1     Document Type: Chapter

References (322)

1. Abdel-Hamid, M., Novotny, L., and Hamza, H. (2001). Liquid chromatographic-mass spectrometric determination of celecoxib in plasma using single-ion monitoring and its use in clinical pharmacokinetics. J. Chromatogr. B: Biomed. Sci. Appl. 753:401-408.
2. Agrawal, S., Ashokraj, Y., Bharatam, P. V., Pillai, O., and Panchagnula, R. (2004). Solid-state characterization of rifampicin samples and its biopharmaceutic relevance. Eur. J. Pharm. Sci. 22:127-144.
3. Alnouti, Y., Srinivasan, K., Waddell, D., Bi, H., Kavetskaia, O., and Gusev, A. I. (2005). Development and application of a new on-line SPE system combined with LC-MS/MS detection for high throughput direct analysis of pharmaceutical compounds in plasma. J. Chromatogr. A 1080:99-106.
4. Anari, M. R., and Baillie, T. A. (2005). Bridging cheminformatic metabolite prediction and tandem mass spectrometry. Drug Discov. Today 10:711-717.
5. Anari, M. R., Sanchez, R. I., Bakhtiar, R., Franklin, R. B., and Baillie, T. A. (2004). Integration of knowledge-based metabolic predictions with liquid chromatography data-dependent tandem mass spectrometry for drug metabolism studies: Application to studies on the biotransformation of indinavir. Anal. Chem. 76:823-832.
6. Avery, M. J. (2003). Quantitative characterization of differential ion suppression on liquid chromatography/atmospheric pressure ionization mass spectrometric bioanalytical methods. Rapid Commun. Mass Spectrom. 17:197-201.
7. Ayrton, J., Dear, G. J., Leavens, W. J., Mallett, D. N., and Plumb, R. S. (1997). The use of turbulent flow chromatography/mass spectrometry for the rapid, direct analysis of a novel pharmaceutical compound in plasma. Rapid Commun. Mass Spectrom. 11:1953-1958.
8. Baillie, T. A., Cayen, M. N., Fouda, H., Gerson, R. J., Green, J. D., Grossman, S. J., Klunk, L. J., LeBlanc, B., Perkins, D. G., and Shipley, L. A. (2002). Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 182(3):188-196.
9. Baillie, T. A., Cayen, M. N., Fouda, H., Gerson, R. J., Green, J. D., Grossman, S. J., Klunk, L. J., LeBlanc, B., Perkins, D. G., and Shipley, L. A. (2003). Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 190(1):93-94.
10. Bakhtiar, R., and Majumdar, T. K. (2007). Tracking problems and possible solutions in the quantitative determination of small molecule drugs and metabolites in biological fluids using liquid chromatography-mass spectrometry. J. Pharmacol. Toxicol. Methods 55:227-243.
11. Bauer, J., Spanton, S., Henry, R., Quick, J., Dziki, W., Porter, W., and Morris, J. (2001). Ritonavir: An extraordinary example of conformational polymorphism. Pharm. Res. 18:859-866.
12. Bayliss, M. A., Antler, M., McGibbon, G., and Lashin, V. (2007). Rapid Metabolite Identification Using Advanced Algorithms for Mass Spectral Interpretation. In Proceedings of the 55th ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Indianapolis, IN.
13. Belov, M. E., Nikolaev, E. N., Alving, K., and Smith, R. D. (2001). A new technique for unbiased external ion accumulation in a quadrupole two-dimensional ion trap for electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry. Rapid Commun. Mass Spectrom. 15:1172-1180.
14. Benkestock, K., Edlund, P. O., and Roeraade, J. (2005). Electrospray ionization mass spectrometry as a tool for determination of drug binding sites to human serum albumin by noncovalent interaction. Rapid Commun. Mass Spectrom. 19:1637-1643.
15. Bonfiglio, R., King, R. C., Olah, T. V., and Merkle, K. (1999). The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Commun. Mass Spectrom. 13:1175-1185.
16. Briem, S., Martinsson, S., Bueters, T., and Skoglund, E. (2007). Combined approach for highthroughput preparation and analysis of plasma samples from exposure studies. Rapid Commun. Mass Spectrom. 21:1965-1972.
17. Briscoe, C. J., Stiles, M. R., and Hage, D. S. (2007). System suitability in bioanalytical LC/MS/MS. J. Pharm. Biomed. Anal. 44:484-491.
18. Bruins, A. P. (1991). Liquid chromatography-mass spectrometry with ionspray and electrospray interfaces in pharmaceutical and biomedical research. J. Chromatogr. 554:39-46.
19. Bu, H. Z., Knuth, K., Magis, L., and Teitelbaum, P. (2001a). High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. V. Validation of a direct injection/on-line guard cartridge extraction-tandem mass spectrometry method for CYP1A2 inhibition assessment. Eur. J. Pharm. Sci. 12:447-452.
20. Bu, H. Z., Knuth, K., Magis, L., and Teitelbaum, P. (2001b). High-throughput cytochrome P450 (CYP) inhibition screening via cassette probe-dosing strategy: III. Validation of a direct injection/on-line guard cartridge extraction-tandem mass spectrometry method for CYP2C19 inhibition evaluation. J. Pharm. Biomed. Anal. 25:437-442.
21. Bu, H. Z., Magis, L., Knuth, K., and Teitelbaum, P. (2000a). High-throughput cytochrome P450 (CYP) inhibition screening via cassette probe-dosing strategy. I. Development of direct injection/on-line guard cartridge extraction/tandem mass spectrometry for the simultaneous detection of CYP probe substrates and their metabolites. Rapid Commun. Mass Spectrom. 14:1619-1624.
22. Bu, H. Z., Magis, L., Knuth, K., and Teitelbaum, P. (2001c). High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing stra. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1. Rapid Commun. Mass Spectrom. 15:741-748.
23. Bu, H. Z., Magis, L., Knuth, K., and Teitelbaum, P. (2001d). High-throughput cytochrome P450 (CYP) inhibition screening via cassette probe-dosing strategy II. Validation of a direct injection/on-line guard cartridge extraction-tandem mass spectrometry method for CYP2D6 inhibition assessment. J. Chromatogr. B: Biomed. Sci. Appl. 753:321-326.
24. Bu, H. Z., Poglod, M., Micetich, R. G., and Khan, J. K. (2000b). High-throughput Caco-2 cell permeability screening by cassette dosing and sample pooling approaches using direct injection/on-line guard cartridge extraction/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 14:523-528.
25. Cai, Y., Kingery, D., McConnell, O., and Bach, A. C. 2nd (2005). Advantages of atmospheric pressure photoionization mass spectrometry in support of drug discovery. Rapid Commun. Mass Spectrom. 19:1717-1724.
26. Cai, Z., Han, C., Harrelson, S., Fung, E., and Sinhababu, A. K. (2001). High-throughput analysis in drug discovery: Application of liquid chromatography/ion-trap mass spectrometry for simultaneous cassette analysis of alpha-1a antagonists and their metabolites in mouse plasma. Rapid Commun. Mass Spectrom. 15:546-550.
27. Cai, Z., Sinhababu, A. K., and Harrelson, S. (2000). Simultaneous quantitative cassette analysis of drugs and detection of their metabolites by high performance liquid chromatography/ion trap mass spectrometry. Rapid Commun. Mass Spectrom. 14:1637-1643.
28. Caskey, C. T. (2007). The drug development crisis: Efficiency and safety. Annu. Rev. Med. 58:1-16.
29. Castro-Perez, J., Plumb, R., Granger, J. H., Beattie, I., Joncour, K., and Wright, A. (2005). Increasing throughput and information content for in vitro drug metabolism experiments using ultra-performance liquid chromatography coupled to a quadrupole time-of-flight mass spectrometer. Rapid Commun. Mass Spectrom. 19:843-848.
30. Cha, B., Blades, M. W., and Douglas, D. J. (2000). An interface with a linear quadrupole ion guide for an electrospray-ion trap mass spectrometer system. Anal. Chem. 72:5647-5654.
31. Chang, M. S., Ji, Q., Zhang, J., and El-Shourbagy, T. A. (2007a). Historical review of sample preparation for chromatographic bioanalysis: Pros and cons. Drug Dev. Res. 68:107-133.
32. Chang, M. S., Kim, E. J., and El-Shourbagy, T. A. (2007b). Evaluation of 384-well formatted sample preparation technologies for regulated bioanalysis. Rapid Commun. Mass Spectrom. 21:64-72.
33. Chavez-Eng, C. M., Constanzer, M. L., and Matuszewski, B. K. (2000). Determination of rofecoxib (MK-0966), a cyclooxygenase-2 inhibitor, in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection. J. Chromatogr. B Biomed. Sci. Appl. 748:31-39.
34. Chen, G., Pramanik, B. N., Liu, Y. H., and Mirza, U. A. (2007). Applications of LC/MS in structure identifications of small molecules and proteins in drug discovery. J. Mass Spectrom. 42:279-287.
35. Chernushevich, I. V., Loboda, A. V., and Thomson, B. A. (2001). An introduction to quadrupole-time-of-flight mass spectrometry. J. Mass Spectrom. 36:849-865.
36. Chowdhury, S. K. (2007). Early Assessment of human metabolism: Why, how, challenges and opportunities. In Proceedings of the 55th ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Indianapolis, IN.
37. Churchwell, M. I., Twaddle, N. C., Meeker, L. R., and Doerge, D. R. (2005). Improving LC-MS sensitivity through increases in chromatographic performance: Comparisons of UPLC-ES/MS/MS to HPLC-ES/MS/MS. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 825:134-143.
38. Cody, R. B., Laramee, J. A., and Durst, H. D. (2005). Versatile new ion source for the analysis of materials in open air under ambient conditions. Anal. Chem. 77:2297-2302.
39. Cohen, L. H., and Gusev, A. I. (2002). Small molecule analysis by MALDI mass spectrometry. Anal. Bioanal. Chem. 373:571-586.
40. Collings, B. A., Campbell, J. M., Mao, D. M., and Douglas, D. J. (2001). Rapid Commun. Mass Spectrom. 15:1777-1795.
41. Corkery, L. J., Pang, H., Schneider, B. B., Covey, T. R., and Siu, K. W. (2005). Automated nanospray using chip-based emitters for the quantitative analysis of pharmaceutical compounds. J. Am. Soc. Mass Spectrom. 16:363-369.
42. Cornett, D. S., Frappier, S. L., and Caprioli, R. M. (2008). Imaging drugs and metabolites in tissue using Fourier transform mass spectrometry. In Proceedings of the 56th ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Denver, CO.
43. Cudiamat, G. (2005). Peaks of Interest. LCGC N. Am. 23:984.
44. Cuyckens, F., Hurkmans, R., Leclercq, L., and Mortishire-Smith, R. (2008). Extracting relevant data out of the MS background. In Proceedings of the 56th ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Denver, CO.
45. Dawson, P. H. (1986). Quadrupole mass analyzers: Performance, design and some recent applications. Mass Spectrom. Rev. 5:1-37.
46. De Buck, S. S., Sinha, V. K., Fenu, L. A., Gilissen, R. A., Mackie, C. E., and Nijsen, M. J. (2007). The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab. Dispos. 35:649-659.
47. Decaestecker, T. N., Clauwaert, K. M., Van Bocxlaer, J. F., Lambert,W. E., Van den Eeckhout, E. G., Van Peteghem, C. H., and De Leenheer, A. P. (2000). Evaluation of automated single mass spectrometry to tandem mass spectrometry function switching for comprehensive drug profiling analysis using a quadrupole time-of-flight mass spectrometer. Rapid Commun. Mass Spectrom. 14:1787-1792.
48. De Maio, W., Hoffmann, M., Carbonara, M., Moore, R., Mutlib, A., and Talaat, R. E. (2008). Identification of drug metabolites by UPLC-MS with isotope pattern directed mass chromatograms and UPLC with radioactivity flow detection. In Proceedings of the 56th ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Denver, CO.
49. Deng, G., and Sanyal, G. (2006). Applications of mass spectrometry in early stages of target based drug discovery. J. Pharm. Biomed. Anal. 40:528-538.
50. Deng, Y., Wu, J. T., Lloyd, T. L., Chi, C. L., Olah, T. V., and Unger, S. E. (2002). High-speed gradient parallel liquid chromatography/tandem mass spectrometry with fully automated sample preparation for bioanalysis: 30 seconds per sample from plasma. Rapid Commun. Mass Spectrom. 16:1116-1123.
51. Deng, Y., Zeng, H., Unger, S. E., and Wu, J. T. (2001). Multiple-sprayer tandem mass spectrometry with parallel high flow extraction and parallel separation for high-throughput quantitation in biological fluids. Rapid Commun. Mass Spectrom. 15:1634-1640.
52. Derendorf, H., and Meibohm, B. (1999). Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: Concepts and perspectives. Pharm. Res. 16:176-185.
53. Devine, J. W., Cline, R. R., and Farley, J. F. (2006). Follow-on biologics: Competition in the biopharmaceutical marketplace. J. Am. Pharm. Assoc. 46:213-221.
54. De vlieger, J., Krabbe, J. G., Commandeur, J. N. M., Vermeulen, N. P. E., Niessen, W. M. A., and Loftus, N. (2007). Characterisation of metabolites generated by mutant cytochromes P450 enzymes using a 3D ion trap-time of flight mass spectrometer. In Proceedings of the 55th ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Indianapolis, IN.
55. DiMasi, J. A. (2001a). New drug development in the United States from 1963 to 1999. Clin. Pharmacol. Ther. 69:286-296.
56. DiMasi, J. A. (2001b). New drug development in the United States from 1963 to 1999. Clin. Pharmacol. Ther. 69:286-296.
57. DiMasi, J. A., Hansen, R.W., and Grabowski, H. G. (2003). The price of innovation: New estimates of drug development costs. J. Health Econ. 22:151-185.
58. Dolan, J. W. (2007). The perfect method, Part V: Changing column selectivity. LCGC N. Am. 25:1014-1020.
59. Dolnikowski, G. G., Kristo, M. J., Enke, C. G., and Watson, J. T. (1988). Int. J. Mass Spectrom. Ion Processes 82:1-15.
60. Dong, M.W. (2007). Ultrahigh-pressure LC in pharmaceutical analysis: Performance and practical issues. LCGC N. Am. 25:656-666.
61. Drews, J. (2000). Drug discovery: A historical perspective. Science 287:1960-1964.
62. Duffin, K. L., Wachs, T., and Henion, J. D. (1992). Atmospheric pressure ion-sampling system for liquid chromatography/mass spectrometry analyses on a benchtop mass spectrometer. Anal. Chem. 64:61-68.
63. Edge, T., Smith, C., Hill, S., Picard, P., Letarte, S., Wilson, I. D., and Vince, P. (2008). Comparison of laser diode thermal desorption (LDTD) source vs LC-MS for the analysis of a theraputic drug in biological extracts. In Proceedings of the 56th ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Denver, CO.
64. Ells, B., Froese, K., Hrudey, S. E., Purves, R. W., Guevremont, R., and Barnett, D. A. (2000). Detection of microcystins using electrospray ionization high-field asymmetric waveform ion mobility mass spectrometry/mass spectrometry. Rapid Commun. Mass Spectrom. 14:1538-1542.
65. Embi, P. J., Acharya, P., McCuistion, M., Kishman, C. P., Haag, D., and Marine, S. (2006). Responding rapidly to FDA drug withdrawals: Design and application of a new approach for a consumer health website. J. Med. Internet Res. 8:e16.
66. Engel, G. L., Farid, N. A., Faul, M. M., Richardson, L. A., and Winneroski, L. L. (2000). Salt form selection and characterization of LY333531 mesylate monohydrate. Int. J. Pharm. 198:239-247.
67. Erve, J. C. L., DeMaio, W., and Talaat, R. E. (2008). Rapid metabolite identification with sub parts-per million mass accuracy from biological matrices by direct infusion nanoelectrospray ionization after clean-up on a ZipTip and LTQ/Orbitrap mass spectrometry. Rapid Commun. Mass Spectrom. 22:3015-3026.
68. Faed, E. M. (1984). Properties of acyl glucuronides. Implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab. Rev. 15:1213-1249.
69. Fang, L., Cournoyer, J., Demee, M., Zhao, J., Tokushige, D., and Yan, B. (2002). Highthroughput liquid chromatography ultraviolet/mass spectrometric analysis of combinatorial libraries using an eight-channel multiplexed electrospray time-of-flight mass spectrometer. Rapid Commun. Mass Spectrom. 16:1440-1447.
70. Fang, L., Demee, M., Cournoyer, J., Sierra, T., Young, C., and Yan, B. (2003). Parallel highthroughput accurate mass measurement using a nine-channel multiplexed electrospray liquid chromatography ultraviolet time-of-flight mass spectrometry system. Rapid Commun. Mass Spectrom. 17:1425-1432.
71. Feng, W. Y. (2004). Mass spectrometry in drug discovery: A current review. Curr. Drug Discov. Technol. 1:295-312.
72. Fernandez-Metzler, C. L., Owens, K. G., Baillie, T. A., and King, R. C. (1999). Rapid liquid chromatography with tandem mass spectrometry-based screening procedures for studies on the biotransformation of drug candidates. Drug Metab. Dispos. 27:32-40.
73. Ferrer, I., and Thurman, E. M. (2007). Importance of the electron mass in the calculations of exact mass by time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 21:2538-2539.
74. Fligge, T. A., and Schuler, A. (2006). Integration of a rapid automated solubility classification into early validation of hits obtained by high throughput screening. J. Pharm. Biomed. Anal. 42:449-454.
75. Food and Drug Administration (2005). Draft Guidance for Industry: Safety Testing of Drug Metabolites. http://www.fda.gov/ohrms/dockets/98fr/2005d-0203-gdl0001.pdf (June, 2005).
76. Food and Drug Administration (2008). Guidance for Industry: Safety Testing of Drug Metabolites. http://www.fda.gov/cder/guidance/6897fnl.pdf (February, 2008).
77. Frank, R. G. (2007). Regulation of follow-on biologics. N. Engl. J. Med. 357:841-843.
78. Fung, E. N., Chu, I., Li, C., Liu, T., Soares, A., Morrison, R., and Nomeir, A. A. (2003). Higher-throughput screening for Caco-2 permeability utilizing a multiple sprayer liquid chromatography/tandem mass spectrometry system. Rapid Commun. Mass Spectrom. 17:2147-2152.
79. Fung, E. N., Chu, I., and Nomeir, A. A. (2004). A computer program for automated data evaluation to support in vitro higher-throughput screening for drug metabolism and pharmacokinetics attributes. Rapid Commun. Mass Spectrom. 18:2046-2052.
80. Furfine, E. S., Baker, C. T., Hale, M. R., Reynolds, D. J., Salisbury, J. A., Searle, A. D., Studenberg, S. D., Todd, D., Tung, R. D., and Spaltenstein, A. (2004). Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob. Agents Chemother. 48:791-798.
81. Gallagher, R. T., Wilson, I. D., and Hobby, K. (2008). New approach for identification of metabolites of a model drug: Partial isotope-enrichment combined with novel mass spectral modeling software. In Proceedings of the 56th ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Denver, CO.
82. General Accountability Office (GAO) (2006). New drug development: Science, business, regulatory, and intellectual property issues cited as hampering drug development Efforts, Report GAO-07-49. GAO, Washington, DC, November 2006.
83. Ghosal, A., Ramanathan, R., Kishnani, N., Chowdhury, S. K., and Alton, K. B. (2005). Cytochrome P450 (CYP) and UDP-glucuronosyltranferase (UGT) enzymes: Role in drug metabolism, polymorphism, and identification of their involvement in drug metabolism. In Identification and Quantification of Drugs, Metabolites and Metabolizing Enzymes by LC-MS (Chowdhury S. K., Ed.). Elsevier, San Diego, CA, pp. 277-336.
84. Goodwin, L., White, S. A., and Spooner, N. (2007). Evaluation of ultra-performance liquid chromatography in the bioanalysis of small molecule drug candidates in plasma. J. Chromatogr. Sci. 45:298-304.
85. Grange, A. H., and Sovocool, G. W. (2008). Automated determination of precursor ion, product ion, and neutral loss compositions and deconvolution of composite mass spectra using ion correlation based on exact masses and relative isotopic abundances. Rapid Commun. Mass Spectrom. 22:2375-2390.
86. Grayson, M. A. (2002). Measuring Mass: From Positive Rays to Proteins. Chemical Heritage Press, Philadelphia, PA.
87. Gritti, F., Martin, M., and Guiochon, G. (2005). Influence of pressure on the properties of chromatographic columns. II. The column hold-up volume. J. Chromatogr. A 1070:13-22.
88. Gross, J. H. (2004). Mass Spectrometry: A Textbook. Springer-Verlag, Berlin.
89. Gu, M., Wang, Y., Zhao, X. G., and Gu, Z. M. (2006). Accurate mass filtering of ion chromatograms for metabolite identification using a unit mass resolution liquid chromatography/mass spectrometry system. Rapid Commun. Mass Spectrom. 20:764-770.
90. Guengerich, F. P. (2006). Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 8:E101-E111.
91. Guevremont, R. (2004). High-field asymmetric waveform ion mobility spectrometry: A new tool for mass spectrometry. J. Chromatogr. A. 1058:3-19.
92. Guillarme, D., Nguyen, D. T. T., Rudaz, S., and Veuthey, J. L. (2007). Recent developments in liquid chromatography: Impact on qualitative and quantitative performance. J. Chromatogr. A 1149:20-29.
93. Hager, J.W. (2002). A new linear ion trap mass spectrometer. Rapid Commun. Mass Spectrom. 16:512-526.
94. Hanold, K. A., Fischer, S. M., Cormia, P. H., Miller, C. E., and Syage, J. A. (2004). Atmospheric pressure photoionization. 1. General properties for LC/MS. Anal. Chem. 76:2842-2851.
95. Hardman, M., and Makarov, A. A. (2003). Interfacing the orbitrap mass analyzer to an electrospray ion source. Anal. Chem. 75:1699-1705.
96. Hashimoto, Y., Waki, I., Yoshinari, K., Shishika, T., and Terui, Y. (2005). Orthogonal trap time-of-flight mass spectrometer using a collisional damping chamber. Rapid Commun. Mass Spectrom. 19:221-226.
97. Hastings, K. L., El-Hage, J., Jacobs, A., Leighton, J., Morse, D., and Osterberg, R. E. (2003). Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 190(1):91-92.
98. Hatsis, P., Brockman, A. H., and Wu, J. T. (2007). Evaluation of high-field asymmetric waveform ion mobility spectrometry coupled to nanoelectrospray ionization for bioanalysis in drug discovery. Rapid Commun. Mass Spectrom. 21:2295-2300.
99. Heinonen, M., Rantanen, A., Mielkainen, T., Kokkonen, J., Kiuru, J., Ketola, R. A., and Rousu, J. (2008). FiD: A software for ab initio structural identification of product ions from tandem mass spectrometric data. Rapid Commun. Mass Spectrom. 22:3043-3052.
100. Herniman, J. M., Bristow, T. W. T., O'Connor, G., Jarvis, J., and Langley, G. J. (2004). Improved precision and accuracy for high-performance liquid chromatography/Fourier transform ion cyclotron resonance mass spectrometric exact mass measurement of small molecules from the simultaneous and controlled introduction of internal calibrants via a second electrospray nebuliser. Rapid Commun. Mass Spectrom. 18:3035-3040.
101. Hill, T. P. (2007). Phase 0 trials: Are they ethically challenged? Clin. Cancer Res. 13:783-784.
102. Hillenkamp, F., Karas, M., Ingendoh, A., and Stahl, B. (1990). Matrix assisted UV-laser desorption/ionization: A new approach to mass spectrometry of large biomolecules. Biol. Mass Spectrom. Proc. Int. Symp. Mass Spectrom. Health Life Sci. 2:49-60.
103. Hofstadler, S. A., and Sannes-Lowery, K. A. (2006). Applications of ESI-MS in drug discovery:Interrogation of noncovalent complexes. Nat. Rev. Drug Discov. 5:585-595.
104. Hop, C. E., Tiller, P. R., and Romanyshyn, L. (2002). In vitro metabolite identification using fast gradient high performance liquid chromatography combined with tandem mass spectrometry. Rapid Commun. Mass Spectrom. 16:212-219.
105. Hop, C. E. C. A., and Prakash, C. (2005). Metabolite identification by LC-MS: Applications in drug discovery and development. In Identification and Quantification of Drugs, Metabolites and Metabolizing Enzymes by LC-MS (Chowdhury, S. K., Ed.). Elsevier, Amsterdam, The Netherlands, pp. 123-158.
106. Hopfgartner, G., and Zell, M. (2005). Q Trap MS: A New Tool for Metabolite Identification. (Korfmacher, W. A., Ed.). CRC Press, Boca Raton, FL, pp. 277-304.
107. Hopfgartner, G., Sleno, L., Loftus, N.,Warrander, J., and Ashton, S. (2007). A statistical based approach in metabolite identification by high mass accuracy MSn analysis. In Proceedings of the 55th ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Indianapolis, IN.
108. Hopfgartner, G., and Vilbois, F. (2000). The impact of accurate mass measurements using quadrupole/time-of-flight mass spectrometry on the characterisation and screening of drug metabolites: Structure elucidation by LC-MS. Analusis 28:906-914.
109. Hopkins, A. L., and Groom, C. R. (2002). The druggable genome. Nat. Rev. Drug Discov. 1:727-730.
110. Hsieh, Y. (2005). APPI: A New Ionization Source for LC-MS/MS Assays. (Korfmacher, W. A., Ed.) CRC Press, Boca Raton, FL, pp. 253-276.
111. Hsieh, Y., and Chen, J. (2005). Simultaneous determination of nicotinic acid and its metabolites using hydrophilic interaction chromatography with tandem mass spectrometry. Rapid Commun. Mass Spectrom. 19:3031-3036.
112. Hsieh, Y., Fukuda, E., Wingate, J., and Korfmacher, W. A. (2006). Fast mass spectrometrybased methodologies for pharmaceutical analyses. Comb. Chem. High Throughput Screening 9:3-8.
113. Hsieh, Y., and Korfmacher,W. A. (2006). Increasing speed and throughput when using HPLCMS/MS systems for drug metabolism and pharmacokinetic screening. Curr. Drug Metab. 7:479-489.
114. Hsieh, Y., Wang, G., Wang, Y., Chackalamannil, S., Brisson, J. M., Ng, K., and Korfmacher, W. A. (2002). Simultaneous determination of a drug candidate and its metabolite in rat plasma samples using ultrafast monolithic column high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 16:944-950.
115. Hsieh, Y., Wang, G., Wang, Y., Chackalamannil, S., and Korfmacher, W. A. (2003). Direct plasma analysis of drug compounds using monolithic column liquid chromatography and tandem mass spectrometry. Anal. Chem. 75:1812-1818.
116. Hu, Q., Noll, R. J., Li, H., Makarov, A., Hardman, M., and Graham Cooks, R. (2005). The Orbitrap: A new mass spectrometer. J. Mass Spectrom. 40:430-443.
117. Huang, L. F., and Tong,W. Q. (2004). Impact of solid state properties on developability assessment of drug candidates. Adv. Drug Deliv. Rev. 56:321-334.
118. Huang, M. Q., Mao, Y., Jemal, M., and Arnold, M. (2006). Increased productivity in quantitative bioanalysis using a monolithic column coupled with high-flow direct-injection liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 20:1709-1714.
119. Hughes, N., Winnik, W., Dunyach, J. J., Amad, M., Splendore, M., and Paul, G. (2003). Highsensitivity quantitation of cabergoline and pergolide using a triple-quadrupole mass spectrometer with enhanced mass-resolution capabilities. J. Mass Spectrom. 38:743-751.
120. Inohana, Y., Hirano, I., Yamaguchi, S., Arakawa, K., Ashton, S., Loftus, N., and Warrander, J. (2007). Structure elucidation of Sildanafil analogues by MSn and accurate mass measurement. In Proceedings of the 55th ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Indianapolis, IN.
121. Ishii, Y., Takami, A., Tsuruda, K., Kurogi, A., Yamada, H., and Oguri, K. (1997). Induction of two UDP-glucuronosyltransferase isoforms sensitive to phenobarbital that are involved in morphine glucuronidation. Production of isoform-selective antipeptide antibodies toward UGT1.1r and UGT2B1. Drug Metab. Dispos. 25:163-167.
122. Ishizuka, N., Minakuchi, H., Nakanishi, K., Soga, N., Nagayama, H., Hosoya, K., and Tanaka, N. (2000). Performance of a monolithic silica column in a capillary under pressure-driven and electrodriven conditions. Anal. Chem. 72:1275-1280.
123. Ives, S., Gjervig-Jensen, K., and McSweeney, N. (2007). Speed up of the identification of the metabolites of Citalopram using LC/MS/MS and in silico prediction. In Proceedings of the 55th ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Indianapolis, IN.
124. Jang, G. R., Harris, R. Z., and Lau, D. T. (2001). Pharmacokinetics and its role in small molecule drug discovery research. Med. Res. Rev. 21:382-396.
125. Jemal, M., Huang, M., Mao, Y., Whigan, D., and Powell, M. L. (2001). Increased throughput in quantitative bioanalysis using parallel-column liquid chromatography with mass spectrometric detection. Rapid Commun. Mass Spectrom. 15:994-999.
126. Jemal, M., and Ouyang, Z. (2003). Enhanced resolution triple-quadrupole mass spectrometry for fast quantitative bioanalysis using liquid chromatography/tandem mass spectrometry:Investigations of parameters that affect ruggedness. Rapid Commun. Mass Spectrom. 17:24-38.
127. Jemal, M., Schuster, A., and Whigan, D. B. (2003). Liquid chromatography/tandem mass spectrometry methods for quantitation of mevalonic acid in human plasma and urine:Method validation, demonstration of using a surrogate analyte, and demonstration of unacceptable matrix effect in spite of use of a stable isotope analog internal standard. Rapid Commun. Mass Spectrom. 17:1723-1734.
128. Jemal, M., and Xia, Y. Q. (2006). LC-MS development strategies for quantitative bioanalysis. Curr. Drug. Metab. 7:491-502.
129. Jerkovich, A. D., LoBrutto, R., and Vivilecchia, R. V. (2005). The use of ACQUITY UPLC in pharmaceutical development. LCGC N. Am.15-21.
130. Jiang, Y., Hall, T. A., Hofstadler, S. A., and Naviaux, R. K. (2007). Mitochondrial DNA mutation detection by electrospray mass spectrometry. Clin. Chem. 53:195-203.
131. Jones, A. B. (2006). Bioanalytical quality assurance: Concepts and concerns. Quality Assur. J. 10:101-106.
132. Johnson, W. W. (2008a). Cytochrome P450 inactivation by pharmaceuticals and phytochemicals:Therapeutic relevance. Drug Metab. Rev. 40:101-147.
133. Johnson, W. W. (2008b). Many drugs and phytochemicals can be activated to biological reactive intermediates. Curr. Drug Metab. 9:344-351.
134. Kantharaj, E., Ehmer, P. B., De Wagter, K., Tuytelaars, A., Proost, P. E., Mackie, C., and Gilissen, R. A. (2005a). The use of liquid chromatography-atmospheric pressure chemical ionization mass spectrometry to explore the in vitro metabolism of cyanoalkyl piperidine derivatives. Biomed. Chromatogr. 19:245-249.
135. Kantharaj, E., Ehmer, P. B., Tuytelaars, A., Van Vlaslaer, A., Mackie, C., and Gilissen, R. A. (2005b). Simultaneous measurement of metabolic stability and metabolite identification of 7-methoxymethylthiazolo[3,2-a]pyrimidin-5-one derivatives in human liver microsomes using liquid chromatography/ion-trap mass spectrometry. Rapid Commun. Mass Spectrom. 19:1069-1074.
136. Kantharaj, E., Tuytelaars, A., Proost, P. E., Ongel, Z., Van Assouw, H. P., and Gilissen, R. A. (2003). Simultaneous measurement of drug metabolic stability and identification of metabolites using ion-trap mass spectrometry. Rapid Commun. Mass Spectrom. 17:2661-2668.
137. Kapron, J. T., Jemal, M., Duncan, G. F., Kolakowski, B. M., and Purves, R. (2005). Removal of metabolite interference during liquid chromatography/tandem mass spectrometry using high-field asymmetric waveform ion mobility spectrometry. Rapid Commun. Mass Spectrom. 19:1979-1983.
138. Kassel, D. B. (2004). Applications of high-throughput ADME in drug discovery. Curr. Opin. Chem. Biol. 8:339-345.
139. Kassel, D. B. (2005). High throughput strategies for in vitro ADME assays: How fast we go?. In Using Mass Spectrometry for Drug Metabolism Studies (Korfmacher, W. A., Ed.). CRC Press, Boca Raton, FL, pp. 83-102.
140. Kauppila, T. J., Wiseman, J. M., Ketola, R. A., Kotiaho, T., Cooks, R. G., and Kostiainen, R. (2006). Desorption electrospray ionization mass spectrometry for the analysis of pharmaceuticals and metabolites. Rapid Commun. Mass Spectrom. 20:387-392.
141. Kebarle, P. (2000). A brief overview of the present status of the mechanisms involved in electrospray mass spectrometry. J. Mass Spectrom. 35:804-817.
142. Kerns, E. H. (2001). High throughput physicochemical profiling for drug discovery. J. Pharm. Sci. 90:1838-1858.
143. Kero, F. H., Pedder, R. E., and Yost, R. A. (2005). Quadrupole mass analyzers: Theoretical and practical considerations. In Encyclopedia of Genetics, Genomics, Proteomics and Bioinformatics, Part 3: Proteomics. Wiley, Hoboken, NJ.
144. Kertesz, V., and Van Berkel, G. J. (2008). Improved imaging resolution in desorption electrospray ionization mass spectrometry. Rapid Commun. Mass Spectrom. 22:2639-2644.
145. Kind, T., and Fiehn, O. (2006). Metabolomic database annotations via query of elemental compositions:Mass accuracy is insufficient even at less than 1 ppm. BMC Bioinformatics 7.
146. Kind, T., Tolstikov, V., Fiehn, O., and Weiss, R. H. (2007). A comprehensive urinary metabolomic approach for identifying kidney cancerr. Anal. Biochem. 363:185-195.
147. King, R. C., Miller-Stein, C., Magiera, D. J., and Brann, J. (2002). Description and validation of a staggered parallel high performance liquid chromatography system for good laboratory practice level quantitative analysis by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 16:43-52.
148. King, R., Bonfiglio, R., Fernandez-Metzler, C., Miller-Stein, C., and Olah, T. (2000). Mechanistic investigation of ionization suppression in electrospray ionization. J. Am. Soc. Mass. Spectrom. 11:942-950.
149. King, R. C., Gundersdorf, R., and Fernandez-Metzler, C. L. (2003). Collection of selected reaction monitoring and full scan data on a time scale suitable for target compound quantitative analysis by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 17:2413-2422.
150. Koal, T., Sibum, M., Koster, E., Resch, K., and Kaever, V. (2006). Direct and fast determination of antiretroviral drugs by automated online solid-phase extraction-liquid chromatography-tandem mass spectrometry in human plasma. Clin. Chem. Lab. Med. 44:299-305.
151. Kobayashi, Y., Ito, S., Itai, S., and Yamamoto, K. (2000). Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate. Int. J. Pharm. 193:137-146.
152. Koers, J. M. (2008). Selected ion monitoring (SIM) mode data collection using the laser diode thermal desorption (LDTD) source to increase sensitivity. In Proceedings of the 56th ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Denver, CO.
153. Kola, I., and Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Rev. 3:711-715.
154. Kolakowski, B. M., Lustig, D., and Purves, R. W. (2004). Separation and quantitation of caffeine metabolites by high-field asymmetric waveform ion mobility spectrometry (FAIMS). In Proceedings of the 52nd ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Nashville, TN.
155. Kopec, K. K., Bozyczko-Coyne, D., and Williams, M. (2005). Target identification and validation in drug discovery: The role of proteomics. Biochem. Pharmacol. 69:1133-1139.
156. Köpke, A. (2006). The proteomics toolbox-A review of the newest drug discovery methods. Business Briefing: Future Drug Discovery. Touch Briefings, London, UK.
157. Korfmacher, W. A. (2005). Bioanalytical assays in a drug discovery environment. In Using Mass Spectrometry for Drug Metabolism Studies (Korfmacher, W. A., Ed.). CRC Press, Boca Raton, FL, pp. 1-34.
158. Korfmacher, W. A., Cox, K. A., Ng, K. J., Veals, J., Hsieh, Y., Wainhaus, S., Broske, L., Prelusky, D., Nomeir, A., and White, R. E. (2001). Cassette-accelerated rapid rat screen:A systematic procedure for the dosing and liquid chromatography/atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery. Rapid Commun. Mass Spectrom. 15:335-340.
159. Kovaleski, J., Kraut, B., Mattiuz, A., Giangiulio, M., Brobst, G., Cagno, W., Kulkarni, P., and Rauch, T. (2007). Impurities in generic pharmaceutical development. Adv. Drug Deliv. Rev. 59:56-63.
160. Kuhlenbeck, D. L., Eichold, T. H., Hoke, S. H., 2nd, Baker, T. R., Mensen, R., andWehmeyer, K. R. (2005). On-line solid phase extraction using the Prospekt-2 coupled with a liquid chromatography/tandem mass spectrometer for the determination of dextromethorphan, dextrorphan and guaifenesin in human plasma. Eur. J. Mass Spectrom. (Chichester, Engl.) 11:199-208.
161. Kummar, S., Kinder, R., Gutierrez, M., Rubinstein, L., Parchment, R., Phillips, L., Low, J., Murgo, A., Tomaszewski, J., and Doroshow, J. (2007). Inhibition of poly (ADP-ribose) polymerase (PARP) by ABT-888 in patients with advanced malignancies: Results of a phase 0 trial. In American Society of Clinical Oncology Meeting. Chicago, IL.
162. Labowsky, M. J., Fenn, J. B., and Yamashita, M. (1984). Method and apparatus for the mass spectrometric analysis of solutions. US patent 84-302751.
163. Lappin, G., and Garner, R. C. (2005). The use of accelerator mass spectrometry to obtain early human ADME/PK data. Expert Opin. Drug Metab. Toxicol. 1:23-31.
164. Lasser, K. E., Allen, P. D., Woolhandler, S. J., Himmelstein, D. U., Wolfe, S. M., and Bor, D. H. (2002). Timing of new black box warnings and withdrawals for prescription medications. JAMA 287:2215-2220.
165. Lebre, D. T., Aiello, M., Impey, G., and Bonelli, F. (2007). Microdosing study in rat plasma using high sensitive LC-ESI/MS/MS technique. In Proceedings of the 55th ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Indianapolis, IN.
166. Lee, M. S. (2005). Integrated Strategies for Drug Discovery Using Mass Spectrometry. Wiley, Hoboken, NJ.
167. Lewin, M., Guilhaus, M., Wildgoose, J., Hoyes, J., and Bateman, B. (2002). Ion dispersion near parallel wire grids in orthogonal acceleration time-of-flight mass spectrometry:Predicting the effect of the approach angle on resolution. Rapid Commun. Mass Spectrom. 16:609-615.
168. Li, M., Alnouti, Y., Leverence, R., Bi, H., and Gusev, A. I. (2005a). Increase of the LC-MS/MS sensitivity and detection limits using on-line sample preparation with large volume plasma injection. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 825:152-160.
169. Li, et al. (2005b). Rapid Commun. Mass Spectrom. 19:1943-1950.
170. Link, A. J. (1999). Direct analysis of protein complexes using mass spectrometry. Nat. Biotechnol. 17:676-682.
171. Lipper, R. A. (1999). How can we optimize selection of drug development candidates from many compounds at the discovery stage? Modern Drug Discov. 2:55.
172. Liu, Y. M., Akervik, K., and Maljers, L. (2006). Optimized high resolution SRM quantitative analysis using a calibration correction method on triple quadrupole system. In Proceedings of the 54th ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Seattle, WA.
173. Ma, S., Chowdhury, S. K., and Alton, K. B. (2006). Application of mass spectrometry for metabolite identification. Curr. Drug. Metab. 7:503-523.
174. Ma, S., and Subramanian, R. (2006). Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometry. J. Mass Spectrom. 41:1121-1139.
175. Mandagere, A. K., Thompson, T. N., and Hwang, K. K. (2002). Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J. Med. Chem. 45:304-311.
176. March, R. E. (1997). An introduction to quadrupole ion trap mass spectrometery. J. Mass Spectrom. 32:351-369.
177. Marshall, A. G., Hendrickson, C. L., and Jackson, G. S. (1998). Fourier transform ion cyclotron resonance mass spectrometry: A primer. Mass Spectrom. Rev. 17:1-35.
178. Martin, M., and Guiochon, G. (2005). Effects of high pressure in liquid chromatography. J. Chromatogr. A 1090:16-38.
179. Martinez, M. N., and Amidon, G. L. (2002). A mechanistic approach to understanding the factors affecting drug absorption: A review of fundamentals. J. Clin. Pharmacol. 42:620-643.
180. Matuszewski, B. K. (2006). Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 830:293-300.
181. Matuszewski, B. K., Constanzer, M. L., and Chavez-Eng, C. M. (1998). Matrix effect in quantitative LC/MS/MS analyses of biological fluids: A method for determination of finasteride in human plasma at picogram per milliliter concentrations. Anal. Chem. 70:882-889.
182. Matuszewski, B. K., Constanzer, M. L., and Chavez-Eng, C. M. (2003). Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 75:3019-3030.
183. Maurer, H. H. (2007). Current role of liquid chromatography-mass spectrometry in clinical and forensic toxicology. Anal. Bioanal. Chem. 388:1315-1325.
184. McCooeye, M., Ding, L., Gardner, G. J., Fraser, C. A., Lam, J., Sturgeon, R. E., and Mester, Z. (2003). Separation and quantitation of the stereoisomers of ephedra alkaloids in natural health products using flow injection-electrospray ionization-high field asymmetric waveform ion mobility spectrometry-mass spectrometry. Anal. Chem. 75:2538-2542.
185. McCooeye, M., and Mester, Z. (2006). Comparison of flow injection analysis electrospray mass spectrometry and tandem mass spectrometry and electrospray high-field asymmetric waveform ion mobility mass spectrometry and tandem mass spectrometry for the determination of underivatized amino acids. Rapid Commun. Mass Spectrom. 20:1801-1808.
186. McCooeye, M. A., Ells, B., Barnett, D. A., Purves, R. W., and Guevremont, R. (2001). Quantitation of morphine and codeine in human urine using high-field asymmetric waveform ion mobility spectrometry (FAIMS) with mass spectrometric detection. J. Anal. Toxicol. 25:81-87.
187. McCooeye, M. A., Mester, Z., Ells, B., Barnett, D. A., Purves, R. W., and Guevremont, R. (2002). Quantitation of amphetamine, methamphetamine, and their methylenedioxy derivatives in urine by solid-phase microextraction coupled with electrospray ionization-high-field asymmetric waveform ion mobility spectrometry-mass spectrometry. Anal. Chem. 74:3071-3075.
188. McEwen, C. N., McKay, R. G., and Larsen, B. S. (2005). Analysis of solids, liquids, and biological tissues using solids probe introduction at atmospheric pressure on commercial LC/MS instruments. Anal. Chem. 77:7826-7831.
189. McGibbon, G. A., Bayliss, M. A., Antler, M., and Lashin, V. (2008). Automated software analysis of isotpe cluster mass differences for components in LC-MS datasets. In Proceedings of the 56th ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Denver, CO.
190. McLean, J. A., Ridenour, W. B., and Caprioli, R. M. (2007). Profiling and imaging of tissues by imaging ion mobility-mass spectrometry. J. Mass Spectrom. 42:1099-1105.
191. Mei, H. (2005). Matrix effects: Causes and solutions. In Using Mass Spectrometry for Drug Metabolism Studies (Korfmacher, W. A., Ed.). CRC Press, Boca Raton, FL, pp. 103-150.
192. Mei, H., Hsieh, Y., Nardo, C., Xu, X., Wang, S., Ng, K., and Korfmacher, W. A. (2003). Investigation of matrix effects in bioanalytical high-performance liquid chromatography/tandem mass spectrometric assays: Application to drug discovery. Rapid Commun. Mass Spectrom. 17:97-103.
193. Mensch, J., Noppe, M., Adriaensen, J., Melis, A., Mackie, C., Augustijns, P., and Brewster, M. E. (2007). Novel generic UPLC/MS/MS method for high throughput analysis applied to permeability assessment in early drug discovery. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 847:182-187.
194. Messina, C. J., Grumbach, E. S., and Diehl, D. M. (2007). Development and validation of a UHPLC method for paroxetine hydrochloride. LCGC N. A. 25:1042-1049.
195. Michael, S. M., Chien, M., and Lubman, D. M. (1992). An ion trap storage/time-of-flight mass spectrometer. Rev. Sci. Instrum. 63:4277-4284.
196. Milne, G. M. (2003). Pharmaceutical productivity: The imperative for a new paradigm. In Annual Reports in Medicinal Chemistry (Doherty, A. M., Ed.). Elsevier, Amsterdam, pp. 383-396.
197. Morris, H. R., Paxton, T., Dell, A., Langhorne, J., Berg, M., Bordoli, R. S., Hoyes, J., and Bateman, R. H. (1996). High sensitivity collisionally-activated decomposition tandem mass spectrometry on a novel quadrupole/orthogonal-acceleration time-of-flight mass spectrometer. Rapid Commun. Mass Spectrom. 10:889-896.
198. Morris, H. R., Paxton, T., Panico, M., McDowell, R., and Dell, A. (1997). A novel geometry mass spectrometer, the Q-TOF, for low-femtomole/attomole-range biopolymer sequencing. J. Protein Chem. 16:469-479.
199. Morrison, D., Davies, A. E., and Watt, A. P. (2002). An evaluation of a four-channel multiplexed electrospray tandem mass spectrometry for higher throughput quantitative analysis. Anal. Chem. 74:1896-1902.
200. Muller, C., Schafer, P., Stortzel, M., Vogt, S., and Weinmann, W. (2002). Ion suppression effects in liquid chromatography-electrospray-ionisation transport-region collision induced dissociation mass spectrometry with different serum extraction methods for systematic toxicological analysis with mass spectra libraries. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 773:47-52.
201. Naidong, W., Addison, T., Schneider, T., Jiang, X., and Halls, T. D. (2003). A sensitive LC/MS/MS method using silica column and aqueous-organic mobile phase for the analysis of loratadine and descarboethoxy-loratadine in human plasma. J. Pharm. Biomed. Anal. 32:609-617.
202. Naidong, W., Bu, H., Chen, Y. L., Shou, W. Z., Jiang, X., and Halls, T. D. (2002a). Simultaneous development of six LC-MS-MS methods for the determination of multiple analytes in human plasma. J. Pharm. Biomed. Anal. 28:1115-1126.
203. Naidong, W., Shou, W. Z., Addison, T., Maleki, S., and Jiang, X. (2002b). Liquid chromatography/tandem mass spectrometric bioanalysis using normal-phase columns with aqueous/organic mobile phases: A novel approach of eliminating evaporation and reconstitution steps in 96-well SPE. Rapid Commun. Mass Spectrom. 16:1965-1975.
204. New, L. S., Saha, S., Ong, M. M. K., Boelsterli, U. A., and Chan, E. C. Y. (2007). Pharmacokinetic study of intraperitoneally administered troglitazone in mice using ultraperformance liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 21:982-988.
205. Newman, D. J., and Cragg, G. M. (2007). Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 70:461-477.
206. Newman, D. J., Cragg, G. M., and Snader, K. M. (2003). Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod. 66:1022-1037.
207. Notari, S., Mancone, C., Tripodi, M., Narciso, P., Fasano, M., and Ascenzi, P. (2006). Determination of anti-HIV drug concentration in human plasma by MALDI-TOF/TOF. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 833:109-116.
208. Obach, R. S., Kalgutkar, A. S., Soglia, J. R., and Zhao, S. X. (2008). Can in vitro metabolismdependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem. Res. Toxicol. 21:1814-1822.
209. O'Connor, D., and Mortishire-Smith, R. (2006). High-throughput bioanalysis with simultaneous acquisition of metabolic route data using ultra performance liquid chromatography coupled with time-of-flight mass spectrometry. Anal. Bioanal. Chem. 385:114-121.
210. O'Connor, D., Mortishire-Smith, R., Morrison, D., Davies, A., and Dominguez, M. (2006). Ultra-performance liquid chromatography coupled to time-of-flight mass spectrometry for robust, high-throughput quantitative analysis of an automated metabolic stability assay, with simultaneous determination of metabolic data. Rapid Commun. Mass Spectrom. 20:851-857.
211. O'Connor, P. B., Pittman, J. L., Thomson, B. A., Budnik, B. A., Cournoyer, J. C., Jebanathirajah, J., Lin, C., Moyer, S., and Zhao, C. (2006). A new hybrid electrospray Fourier transform mass spectrometer: Design and performance characteristics. Rapid Commun. Mass Spectrom. 20:259-266.
212. Panchagnula, R., and Agrawal, S. (2004). Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin. Int. J. Pharm. 271:1-4.
213. Patrick, J. E., Kosoglou, T., Stauber, K. L., Alton, K. B., Maxwell, S. E., Zhu, Y., Statkevich, P., Iannucci, R., Chowdhury, S., Affrime, M., and Cayen, M. N. (2002). Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab. Dispos. 30:430-437.
214. Patrie, S. M., Charlebois, J. P., Whipple, D., Kelleher, N. L., Hendrickson, C. L., Quinn, J. P., Marshall, A. G., and Mukhopadhyay, B. (2004). Construction of a hybrid quadrupole/Fourier transform ion cyclotron resonance mass spectrometer for versatile MS/MS above 10 kDa. J. Am. Soc. Mass. Spectrom. 15:1099-1108.
215. Paul, G., Winnik, W., Hughes, N., Schweingruber, H., Heller, R., and Schoen, A. (2003). Accurate mass measurement at enhanced mass-resolution on a triple quadrupole mass-spectrometer for the identification of a reaction impurity and collisionally-induced fragment ions of cabergoline. Rapid Commun. Mass Spectrom. 17:561-568.
216. Pedraglio, S., Rozio, M. G., Misiano, P., Reali, V., Dondio, G., and Bigogno, C. (2007). New perspectives in bio-analytical techniques for preclinical characterization of a drug candidate: UPLC-MS/MS in in vitro metabolism and pharmacokinetic studies. J. Pharm. Biomed. Anal. 44:665-673.
217. Pelkonen, O., and Raunio, H. (2005). In vitro screening of drug metabolism during drug development:Can we trust the predictions? Expert Opin. Drug Metab. Toxicol. 1:49-59.
218. Perng, C. Y., Kearney, A. S., Palepu, N. R., Smith, B. R., and Azzarano, L. M. (2003). Assessment of oral bioavailability enhancing approaches for SB-247083 using flowthrough cell dissolution testing as one of the screens. Int. J. Pharm. 250:147-156.
219. Peterman, S. M., Dufresne, C. P., and Horning, S. (2005). The use of a hybrid linear trap/FTICR mass spectrometer for on-line high resolution/high mass accuracy bottom-up sequencing. J. Biomol. Tech. 16:112-124.
220. PhRMA (2006). Pharmaceutical Industry Profile 2006. Pharmaceutical Research and Manufacturers of America, Washington, DC.
221. Plumb, R., Castro-Perez, J., Granger, J., Beattie, I., Joncour, K., and Wright, A. (2004). Ultraperformance liquid chromatography coupled to quadrupole-orthogonal time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 18:2331-2337.
222. Prakash, C., Shaffer, C. L., and Nedderman, A. (2007). Analytical strategies for identifying drug metabolites. Mass Spectrom. Rev.
223. Prentis, R. A., Lis, Y., and Walker, S. R. (1988). Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br. J. Clin. Pharmacol. 25:387-396.
224. Prueksaritanont, T., Lin, J. H. et al. (2006). Complicating factors in safety testing of drug metabolites: Kinetic differences between generated and preformed metabolites. Toxicol. Appl. Pharmacol. 217(2):143-152.
225. Purves, R. W., and Guevremont, R. (1999). Electrospray ionization high-field asymmetric waveform ion mobility spectrometry-mass spectrometry. Anal. Chem. 71:2346-2357.
226. Purves, R. W., Guevremont, R., Day, S., Pipich, C. W., and Matyjaszczyk, M. S. (1998). Mass spectrometric characterization of a high-field asymmetric waveform ion mobility spectrometer. Rev. Sci. Instrum. 69:4094-4105.
227. Ramanathan, R., Chowdhury, S. K., and Alton, K. B. (2005). Oxidative metabolites of drugs and xenobiotics: LC-MS methods to identify and characterize in biological matrices. In Identification and Quantification of Drugs, Metabolites and Metabolizing Enzymes by LC-MS (Chowdhury, S. K., Ed.). Elsevier, Amsterdam, The Netherlands, pp. 225-276.
228. Ramanathan, R., Reyderman, L., Kulmatycki, K., Su, A. D., Alvarez, N., Chowdhury, S. K., Alton, K. B., Wirth, M. A., Clement, R. P., Statkevich, P., and Patrick, J. E. (2007a). Disposition of loratadine in healthy volunteers. Xenobiotica 37:753-769.
229. Ramanathan, R., Reyderman, L., Su, A. D., Alvarez, N., Chowdhury, S. K., Alton, K. B., Wirth, M. A., Clement, R. P., Statkevich, P., and Patrick, J. E. (2007b). Disposition of desloratadine in healthy volunteers. Xenobiotica 37:770-787.
230. Ramanathan, R., Zhong, R., Blumenkrantz, N., Chowdhury, S. K., and Alton, K. B. (2007c). Response normalized liquid chromatography nanospray ionization mass spectrometry. J. Am. Soc. Mass. Spectrom. 18:1891-1899.
231. Ramanathan, R., Zhong, R., Blumenkrantz, N., Chowdhury, S. K., and Alton, K. B. (2007d). Quantitative assessment of metabolites early in the clinical program: Potential for using LCNanospray-MS. Eastern Analytical Symposium and Exposition, Somerset, NJ.
232. Romanyshyn, L., Tiller, P. R., Alvaro, R., Pereira, A., and Hop, C. E. C. A. (2001). Ultra-fast gradient vs. fast isocratic chromatography in bioanalytical quantification by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 15:313-319.
233. Romanyshyn, L., Tiller, P. R., and Hop, C. E. (2000). Bioanalytical applications of "fast chromatography" to high-throughput liquid chromatography/tandem mass spectrometric quantitation. Rapid Commun. Mass Spectrom. 14:1662-1668.
234. Ruan, Q., Peterman, S., Szewc, M. A., Ma, L., Cui, D., Humphreys, W. G., and Zhu, M. (2008). An integrated method for metabolite detection and identification using a linear ion trap/Orbitrap mass spectrometer and multiple data processing techniques:Application to indinavir metabolite detection. J. Mass Spectrom. 43:251-261.
235. Rudewicz, P. J., and Yang, L. (2001). Novel approaches to high throughput quantitative LC-MS/MS in a regulated environment. Am. Pharm. Rev. 4:64, 66, 68, 70.
236. Sadek, P. C. (2000). Troubleshooting HPLC Systems: A Bench Manual. Wiley, New York.
237. Salem, I. I., Idrees, J., and Al Tamimi, J. I. (2004). Determination of glimepiride in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 799:103-109.
238. Sanders, M., Shipkova, P. A., Zhang, H., and Warrack, B. M. (2006). Utility of the hybrid LTQ-FTMS for drug metabolism applications. Curr. Drug Metab. 7:547-555.
239. Schwartz, J. C., Senko, M. W., and Syka, J. E. P. (2002). A two-dimensional quadrupole ion trap mass spectrometer. J. Am. Soc. Mass. Spectrom. 13:659-669.
240. Senko, M. W., Hendrickson, C. L., Emmett, M. R., Shi, S. D. H., and Marshall, A. G. (1997). J. Am. Soc. Mass Spectrom. 8:970-976.
241. Seto, C., Ni, J., Ouyang, F., Ellis, R., Aiello, M., Jones, E. B., Welty, D., and Acheampong, A. (2007). Detection of circulating metabolites of carbamazepine in microdosing studies in rats using LC-MS/MS. In Proceedings of the 55th ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Indianapolis, IN.
242. Shah, V. P. (2007). The history of bioanalytical method validation and regulation: Evolution of a guidance document on bioanalytical methods validation. AAPS J. 9:E43-E47.
243. Shah, V. P., Midha, K. K., Findlay, J. W., Hill, H. M., Hulse, J. D., McGilveray, I. J., McKay, G., Miller, K. J., Patnaik, R. N., Powell, M. L., Tonelli, A., Viswanathan, C. T., and Yacobi, A. (2000). Bioanalytical method validation: A revisit with a decade of progress. Pharm. Res. 17:1551-1557.
244. Shen, J. X., Wang, H., Tadros, S., and Hayes, R. N. (2006). Orthogonal extraction/chromatography and UPLC, two powerful new techniques for bioanalytical quantitation of desloratadine and 3-hydroxydesloratadine at 25 pg/mL. J. Pharm. Biomed. Anal. 40:689-706.
245. Siegel, M. M. (2005). Mass-Spectrometry-Based Drug Screening Assays for Early Phases in Drug Discovery. Wiley, Hoboken, NJ.
246. Smalley, J., Marino, A. M., Xin, B., Olah, T., and Balimane, P. V. (2007). Development of a quantitative LC-MS/MS analytical method coupled with turbulent flow chromatography for digoxin for the in vitro P-gp inhibition assay. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 854:260-267.
247. Smith, D. A., Jones, B. C., and Walker, D. K. (1996). Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med. Res. Rev. 16:243-266.
248. Smith, D. A. and Obach, R. S. (2005). Seeing through the mist: abundance versus percentage. Commentary on metabolites in safety testing. Drug. Metab. Dispos. 33(10):1409-1417.
249. Smith, D. A., and Obach, R. S. (2006). Metabolites and safety: what are the concerns, and how should we address them? Chem. Res. Toxicol. 19:1570-1579.
250. Sobott, F., Hernandez, H., McCammon, M. G., Tito, M. A., and Robinson, C. V. (2002). A tandem mass spectrometer for improved transmission and analysis of large macromolecular assemblies. Anal. Chem. 74:1402-1407.
251. Souverain, S., Rudaz, S., and Veuthey, J. L. (2004a). Matrix effect in LC-ESI-MS and LCAPCI-MS with off-line and on-line extraction procedures. J. Chromatogr. A 1058:61-66.
252. Souverain, S., Rudaz, S., and Veuthey, J. L. (2004b). Restricted access materials and large particle supports for on-line sample preparation: An attractive approach for biological fluids analysis. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 801:141-156.
253. Sparkman, O. D. (2006). Mass Spec Desk Reference. Global View Publishing, Pittsburgh, PA.
254. Srinivas, N. R. (2007). Changing need for bioanalysis during drug development. Biomed. Chromatogr. 22:235-243.
255. Stokvis, E., Rosing, H., and Beijnen, J. H. (2005). Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography/mass spectrometry: Necessity or not? Rapid Commun. Mass Spectrom. 19:401-407.
256. Sun, J., Wang, G., Wang, W., Zhao, S., Gu, Y., Zhang, J., Huang, M., Shao, F., Li, H., Zhang, Q., and Xie, H. (2005). Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. J. Pharm. Biomed. Anal. 39:217-224.
257. Swartz, M. E. (2005a). Ultra performance liquid chromatography (UPLC): An introduction. LCGC N. Am. 8-14.
258. Swartz, M. E. (2005b). UPLC. An introduction and review. J. Liq. Chromatogr. Relat. Technol. 28:1253-1263.
259. Sweeney, D. L. (2003). Small molecules asmathematical partitions. Anal. Chem. 75:5362-5373.
260. Syage, J. A., Hanold, K. A., Lynn, T. C., Horner, J. A., and Thakur, R. A. (2004). Atmospheric pressure photoionization. II. Dual source ionization. J. Chromatogr. A 1050:137-149.
261. Takats, Z., Wiseman, J. M., and Cooks, R. G. (2005). Ambient mass spectrometry using desorption electrospray ionization (DESI): Instrumentation, mechanisms and applications in forensics, chemistry, and biology. J. Mass Spectrom. 40:1261-1275.
262. Tall, A. R., Yvan-Charvet, L., and Wang, N. (2007). The failure of torcetrapib: Was it the molecule or the mechanism? Arterioscler. Thromb. Vasc. Biol. 27:257-260.
263. Tanaka, et al. (2002). J. Chromatogr. A 965:35-49.
264. Tang, L., Fitch, W. L., Alexander, M. S., and Dolan, J. W. (2000). Expediting the method development and quality control of reversed-phase liquid chromatography electrospray ionization mass spectrometry for pharmaceutical analysis by using an LC/MS performance test mix. Anal. Chem. 72:5211-5218.
265. Tennikova, T. B., Svec, F., and Belenkii, B. G. (1990). High-performance membrane chromatography. A novel method of protein separation. J. Liquid Chromatogr. Related Technol. 13:63-70.
266. Tiller, P. R., Yu, S., Castro-Perez, J., Fillgrove, K. L., and Baillie, T. A. (2008). High-throughput, accurate mass liquid chromatography/tandem mass spectrometry on a quadrupole time-offlight system as a 'first-line' approach for metabolite identification studies. Rapid Commun. Mass Spectrom. 22:1053-1061.
267. Testa, B., Balmat, A. L., Long, A., and Judson, P. (2005). Predicting drug metabolism: An evaluation of the expert system METEOR. Chem Biodivers 2:872-885.
268. Thompson, T. N. (2000). Early ADME in support of drug discovery: The role of metabolic stability studies. Curr. Drug. Metab. 1:215-241.
269. Thompson, T. N. (2001). Optimization of metabolic stability as a goal of modern drug design. Med. Res. Rev. 21:412-449.
270. Thompson, T. N. (2005). Drug metabolism in vitro and in vivo results: How do these data support drug discovery? In Using Mass Spectrometry for Drug Metabolism Studies (Korfmacher, W. A., Ed.). CRC Press, Boca Raton, FL, pp. 35-81.
271. Thurman, E. M. (2006). Accurate-mass identification of chlorinated and brominated products of 4-nonylphenol, nonylphenol dimers, and other endocrine disrupters. J. Mass Spectrom. 41:1287-1297.
272. Tolley, L., Jorgenson, J.W., and Moseley, M. A. (2001). Very high pressure gradient LC/MS/MS. Anal. Chem. 73:2985-2991.
273. Tong, X., Ita, I. E., Wang, J., and Pivnichny, J. V. (1999). Characterization of a technique for rapid pharmacokinetic studies of multiple co-eluting compounds by LC/MS/MS. J. Pharm. Biomed. Anal. 20:773-784.
274. Tremblay, P., Groleau, P. E., Ayotte, C., Picard, P., and Viel, E. (2008). High-throughput screening and quantification of doping agents in urine using LDTD-APCI-MS/MS. In Proceedings of the 56th ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Denver, CO.
275. Unger, K. K., Skudas, R., and Schult, M. M. (2008). Particle packed columns and monolithic columns in high-performance liquid chromatography-comparison and critical appraisal. J. Chromatogr. A. 1184:393-415.
276. Van Arnum, P. (2007). Advancing approaches in detecting polymorphism. Pharm. Technol. 16:S18-S23.
277. van Deemter, J. J., Zuiderweg, F. J., and Klinkenbergm, A. (1956). Longitudinal diffusion and resistance to mass transfer as causes of nonideality in chromatography. Chem. Eng. Sci. 5:271-289.
278. van De Waterbeemd, H., Smith, D. A., Beaumont, K., and Walker, D. K. (2001). Propertybased design: Optimization of drug absorption and pharmacokinetics. J. Med. Chem. 44:1313-1333.
279. van Pelt, C. K., Corso, T. N., Schultz, G. A., Lowes, S., and Henion, J. (2001). A four-column parallel chromatogr.aphy system for isocratic or gradient LC/MS analyses. Anal. Chem. Pharm. Technol. 16:S18-S23.
280. Venne, K., Bonneil, E., Eng, K., and Thibault, P. (2004). Enhancement in proteomics analyses using nano LC-MS and FAIMS. PharmaGenomics 4:30-32, 34, 36, 38, 40.
281. Venne, K., Bonneil, E., Eng, K., and Thibault, P. (2005). Improvement in peptide detection for proteomics analyses using nano LC-MS and high-field asymmetry waveform ion mobility mass spectrometry. Anal. Chem. 77:2176-2186.
282. Vesell, E. S. (1974). Relationship between drug distribution and therapeutic effects in man. Annu. Rev. Pharmacol. 14:249-270.
283. Viswanathan, C. T., Bansal, S., Booth, B., Destefano, A. J., Rose, M. J., Sailstad, J., Shah, V. P., Skelly, J. P., Swann, P. G., and Weiner, R. (2007). Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays. Pharm. Res. 24:1962-1973.
284. Vlase, L., Imre, S., Muntean, D., and Leucuta, S. E. (2007). Determination of loratadine and its active metabolite in human plasma by high-performance liquid chromatography with mass spectrometry detection. J. Pharm. Biomed. Anal. 44:652-657.
285. Wahlstrom, J. L., Rock, D. A., Slatter, J. G., and Wienkers, L. C. (2006). Advances in predicting CYP-mediated drug interactions in the drug discovery setting. Expert Opin. Drug Discov. 1:677-691.
286. Wang, G., Hsieh, Y., Cui, X., Cheng, K. C., and Korfmacher,W. A. (2006). Ultra-performance liquid chromatography/tandem mass spectrometric determination of testosterone and its metabolites in in vitro samples. Rapid Commun. Mass Spectrom. 20:2215-2221.
287. Watson, J. T., and Sparkman, O. D. (2007). Introduction to Mass Spectrometry:Instrumentation, Applications, and Strategies for Data Interpretation. John Wiley & Sons, Inc., New York, NY.
288. Weaver, P. J., Laures, A. M. F., and Wolff, J. C. (2007). Investigation of the advanced functionalities of a hybrid quadrupole orthogonal acceleration time-of-flight mass spectrometer. Rapid Commun. Mass Spectrom. 21:2415-2421.
289. Weaver, R., and Riley, R. J. (2006). Identification and reduction of ion suppression effects on pharmacokinetic parameters by polyethylene glycol 400. Rapid Commun. Mass Spectrom. 20:2559-2564.
290. Webster, G. K., Li, H., Sanders, W. J., Basel, C. L., and Huang, G. (2001). Column robustness case study for a liquid chromatographic method validated in compliance with ICH, VICH, and GMP guidelines. J. Chromatogr. Sci. 39:273-279.
291. Weng, N., and Halls, T. D. J. (2001). Systematic troubleshooting for LC/MS/MS Part 1:Sample preparation and chromatography. BioPharm. 14:28, 30, 32, 34, 36, 38.
292. Weng, N., and Halls, T. D. J. (2002). Systematic troubleshooting for LC/MS/MS-Part 2:Large-scale LC/MS/MS and automation. BioPharm. 15:22-27.
293. Werner, U., Werner, D., Mundkowski, R., Gillich, M., and Brune, K. (2001). Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans. J. Chromatogr. B Biomed. Sci. Appl. 760:83-90.
294. Werner, U., Werner, D., Pahl, A., Mundkowski, R., Gillich, M., and Brune, K. (2002). Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. Biomed. Chromatogr. 16:56-60.
295. Whalen, K. M., Rogers, K. J., Cole, M. J., and Janiszewski, J. S. (2000). AutoScan: An automated workstation for rapid determination of mass and tandem mass spectrometry conditions for quantitative bioanalytical mass spectrometry. Rapid Commun. Mass Spectrom. 14:2074-2079.
296. Wickremsinhe, E. R., Singh, G., Ackermann, B. L., Gillespie, T. A., and Chaudhary, A. K. (2006). A review of nanoelectrospray ionization applications for drug metabolism and pharmacokinetics. Curr. Drug Metab. 7:913-928.
297. Wieboldt, R., Campbell, D. A., and Henion, J. (1998). Quantitative liquid chromatographictandem mass spectrometric determination of orlistat in plasma with a quadrupole ion trap. J. Chromatogr. B Biomed. Sci. Appl. 708:121-129.
298. Wieling, J. (2002). LC-MS-MS experiences with internal standards. Chromatographia 55:S107-S113.
299. Williams, J. P., Patel, V. J., Holland, R. D., and Scrivens, J. H. (2006). The use of recently described ionization techniques for the rapid analysis of some common drugs and samples of biological origin. Rapid Commun. Mass Spectrom. 20:1447-1456.
300. Wilm, M., and Mann, M. (1996). Analytical properties of the nanoelectrospray ion source. Anal. Chem. 68:1-8.
301. Wilson, D. M., Wang, X., Walsh, E., and Rourick, R. A. (2001). High throughput log D determination using liquid chromatography-mass spectrometry. Comb. Chem. High Throughput Screen. 4:511-519.
302. Wiseman, J. M., Takats, Z., Gologan, B., Davisson, V. J., and Cooks, R. G. (2005). Direct characterization of enzyme-substrate complexes by using electrosonic spray ionization mass spectrometry. Angew Chem. Int. Ed. Engl. 44:913-916.
303. Wren, S. A. C. (2005). Peak capacity in gradient ultra performance liquid chromatography (UPLC). J. Pharm. Biomed. Anal. 38:337-343.
304. Wu, J. T., Zeng, H., Deng, Y., and Unger, S. E. (2001). High-speed liquid chromatography/tandem mass spectrometry using a monolithic column for high-throughput bioanalysis. Rapid Commun. Mass Spectrom. 15:1113-1119.
305. Wu, S. T., Xia, Y. Q., and Jemal, M. (2007). High-field asymmetric waveform ion mobility spectrometry coupled with liquid chromatography/electrospray ionization tandem mass spectrometry (LC/ESI-FAIMS-MS/MS) multicomponent bioanalytical method development, performance evaluation and demonstration of the constancy of the compensation voltage with change of mobile phase composition or flow rate. Rapid Commun. Mass Spectrom. 21:3667-3676.
306. Xia, Y. Q., Hop, C. E., Liu, D. Q., Vincent, S. H., and Chiu, S. H. (2001). Parallel extraction columns and parallel analytical columns coupled with liquid chromatography/tandem mass spectrometry for on-line simultaneous quantification of a drug candidate and its six metabolites in dog plasma. Rapid Commun. Mass Spectrom. 15:2135-2144.
307. Xu, R. N., Fan, L., Rieser, M. J., and El-Shourbagy, T. A. (2007). Recent advances in high-throughput quantitative bioanalysis by LC-MS/MS. J. Pharm. Biomed. Anal. 44:342-355.
308. Xu, X. (2005). Utilizing higher mass resolution in quantitative assays. In Using Mass Spectrometry for Drug Metabolism Studies (Korfmacher, W. A., Ed.). CRC Press, Boca Raton, FL, pp. 203-228.
309. Xu, X., Veals, J., and Korfmacher, W. A. (2003). Comparison of conventional and enhanced mass resolution triple-quadrupole mass spectrometers for discovery bioanalytical applications. Rapid Commun. Mass Spectrom. 17:832-837.
310. Xue, Y. J., Liu, J., Pursley, J., and Unger, S. (2006). A 96-well single-pot protein precipitation, liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for the determination of muraglitazar, a novel diabetes drug, in human plasma. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 831:213-222.
311. Yamane, N., Tozuka, Z., Sugiyama, Y., Tanimoto, T., Yamazaki, A., and Kumagai, Y. (2007). Microdose clinical trial: Quantitative determination of fexofenadine in human plasma using liquid. J. Chromatogr. B 858:118-128.
312. Yang, L., Amad, M., Winnik, W. M., Schoen, A. E., Schweingruber, H., Mylchreest, I., and Rudewicz, P. J. (2002). Investigation of an enhanced resolution triple quadrupole mass spectrometer for high-throughput liquid chromatography/tandem mass spectrometry assays. Rapid Commun. Mass Spectrom. 16:2060-2066.
313. Yang, L., Clement, R. P., Kantesaria, B., Reyderman, L., Beaudry, F., Grandmaison, C., Di Donato, L., Masse, R., and Rudewicz, P. J. (2003). Validation of a sensitive and automated 96-well solid-phase extraction liquid chromatography-tandem mass spectrometry method for the determination of desloratadine and 3-hydroxydesloratadine in human plasma. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 792:229-240.
314. Yang, L., Mann, T. D., Little, D., Wu, N., Clement, R. P., and Rudewicz, P. J. (2001a). Evaluation of a four-channel multiplexed electrospray triple quadrupole mass spectrometer for the simultaneous validation of LC/MS/MS methods in four different preclinical matrixes. Anal. Chem. 73:1740-1747.
315. Yang, L., Wu, N., and Rudewicz, P. J. (2001b). Applications of new liquid chromatographytandem mass spectrometry technologies for drug development support. J. Chromatogr. A 926:43-55.
316. Yao, M., Swaminathan, A., and Srinivas, N. (2007). Assessment of dose proportionality of muraglitazar after repeated oral dosing in rats via a sparse sampling methodology. Biopharm. Drug Dispos. 28:35-42.
317. Yu, K., Di, L., Kerns, E. H., Li, S. Q., Alden, P., and Plumb, R. S. (2007). Ultra-performance liquid chromatography/tandem mass spectrometric quantification of structurally diverse drug mixtures using an ESI-APCI multimode ionization source. Rapid Commun. Mass Spectrom. 21:893-902.
318. Yu, K., Little, D., Plumb, R., and Smith, B. (2006). High-throughput quantification for a drug mixture in rat plasma-A comparison of ultra performance liquid chromatography/tandem mass spectrometry with high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 20:544-552.
319. Zhang, D.,Wang, L., Raghavan, N., Zhang, H., Li, W., Cheng, P. T., Yao, M., Zhang, L., Zhu, M., Bonacorsi, S., Yeola, S., Mitroka, J., Hariharan, N., Hosagrahara, V., Chandrasena, G., Shyu, W. C., and Humphreys, W. G. (2007). Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. Drug Metab. Dispos. 35:150-167.
320. Zhang, H., and Henion, J. (2001). Comparison between liquid chromatography-time-of-flight mass spectrometry and selected reaction monitoring liquid chromatography-mass spectrometry for quantitative determination of idoxifene in human plasma. J. Chromatogr. B Biomed. Sci. Appl. 757:151-159.
321. Zhang, N., Fountain, S. T., Bi, H., and Rossi, D. T. (2000). Quantification and rapid metabolite identification in drug discovery using API time-of-flight LC/MS. Anal. Chem. 72:800-806.
322. Zweigenbaum, J., and Henion, J. (2000). Bioanalytical high-throughput selected reaction monitoring-LC/MS determination of selected estrogen receptor modulators in human plasma: 2000 samples/day. Anal. Chem. 72:2446-2454.